This prospective randomized clinical pilot study was conducted to evaluate a recently introduced reduced volume CPB system that is coated with the biopassive Xcoating(TM). Twenty-two patients undergoing coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB), either with a fully heparin-coated CPB circuit (control, n =11) or with an Xcoating(TM) coated condensed extra-corporeal circuit (CondECC, n =11), were included. We examined activation of the complement system (C3bc and C4bc), activation of neutrophils (BPI), the acute phase response (interleukin (IL)-6, and acute phase proteins (LBP, AGP, and CRP)), myocardial tissue injury (troponin T), hemolysis (free hemoglobin (FHb)), and clinical outcome parameters. Preoperative risk profiles were identical for both patient groups. All patients went through the procedure without major complications and were discharged from the hospital. FHb and BPI levels at the end of pump support (p circulation.
Fransen, E. J., Ganushchak, Y. M., Vijay, V., de Jong, D. S., Buurman, W. A., & Maessen, J. G. (2005). Evaluation of a new condensed extra-corporeal circuit for cardiac surgery: a prospective randomized clinical pilot study. Perfusion, 20 (2), 91-99. https://doi.org/10.1191/0267659105pf795oa